{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T20:56:42Z","timestamp":1794603402818,"version":"4.9.1"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T00:00:00Z","timestamp":1705968000000},"content-version":"vor","delay-in-days":114,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Ocular Surface"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.jtos.2023.10.001","type":"journal-article","created":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T11:36:49Z","timestamp":1696678609000},"page":"254-262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Perfluorohexyloctane in dry eye disease: A systematic review of its efficacy and safety as a novel therapeutic agent"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9248-8685","authenticated-orcid":false,"given":"Antonio","family":"Ballesteros-S\u00e1nchez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concepci\u00f3n","family":"De-Hita-Cantalejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Carmen","family":"S\u00e1nchez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zane","family":"Jansone-Langine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Alvarez","family":"de Sotomayor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josip","family":"Culig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9-Mar\u00eda","family":"S\u00e1nchez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtos.2023.10.001_bib1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jtos.2017.05.005","article-title":"TFOS DEWS II introduction","volume":"15","author":"Nelson","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2023.10.001_bib2","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","article-title":"TFOS DEWS II epidemiology report","volume":"15","author":"Stapleton","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2023.10.001_bib3","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","article-title":"TFOS DEWS II management and therapy report","volume":"15","author":"Jones","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2023.10.001_bib4","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","article-title":"TFOS DEWS II definition and classification report","volume":"15","author":"Craig","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2023.10.001_bib5","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jtos.2017.05.011","article-title":"TFOS DEWS II pathophysiology report","volume":"15","author":"Bron","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2023.10.001_bib6","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jtos.2017.05.001","article-title":"TFOS DEWS II diagnostic methodology report","volume":"15","author":"Wolffsohn","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2023.10.001_bib7","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jtos.2017.05.002","article-title":"TFOS DEWS II pain and sensation report","volume":"15","author":"Belmonte","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2023.10.001_bib8","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jtos.2017.03.006","article-title":"TFOS DEWS II tear film report","volume":"15","author":"Willcox","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2023.10.001_bib9","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1089\/jop.2015.0048","article-title":"Semifluorinated alkane eye drops for treatment of dry eye disease-A prospective, multicenter noninterventional study","volume":"31","author":"Steven","year":"2015","journal-title":"J Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.jtos.2023.10.001_bib10","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1089\/jop.2017.0042","article-title":"Semifluorinated alkane eye drops for treatment of dry eye disease due to meibomian gland disease","volume":"33","author":"Steven","year":"2017","journal-title":"J Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.jtos.2023.10.001_bib11","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jtos.2019.02.010","article-title":"Preclinical studies evaluating the effect of semifluorinated alkanes on ocular surface and tear fluid dynamics","volume":"17","author":"Agarwal","year":"2019","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2023.10.001_bib12","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1089\/jop.2019.0092","article-title":"Influence of perfluorohexyloctane eye drops on tear film thickness in patients with mild to moderate dry eye disease: a randomized controlled clinical trial","volume":"36","author":"Schmidl","year":"2020","journal-title":"J Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.jtos.2023.10.001_bib13","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ajo.2023.03.008","article-title":"NOV03 for signs and symptoms of dry eye disease associated with meibomian gland dysfunction: the randomized phase 3 MOJAVE study","volume":"252","author":"Sheppard","year":"2023","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2023.10.001_bib14","doi-asserted-by":"crossref","DOI":"10.1001\/jamaophthalmol.2023.0270","article-title":"Perfluorohexyloctane eye drops for dry eye disease associated with meibomian gland dysfunction in Chinese patients","author":"Tian","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jtos.2023.10.001_bib15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejpb.2010.05.011","article-title":"Semifluorinated alkanes--a new class of excipients suitable for pulmonary drug delivery","volume":"76","author":"Tsagogiorgas","year":"2010","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.jtos.2023.10.001_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.709712","article-title":"Deciphering the action of perfluorohexyloctane eye drops to reduce ocular discomfort and pain","volume":"8","author":"Delicado-Miralles","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.jtos.2023.10.001_bib17","doi-asserted-by":"crossref","DOI":"10.1001\/jamaophthalmol.2023.0399","article-title":"Will the long-named perfluorohexyloctane produce long-lasting improvements in patients with meibomian gland disease?","author":"Seitzman","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jtos.2023.10.001_bib18","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1097\/ICO.0000000000002622","article-title":"A randomized clinical study (SEECASE) to assess efficacy, safety, and tolerability of NOV03 for treatment of dry eye disease","volume":"40","author":"Tauber","year":"2021","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2023.10.001_bib19","first-page":"18","article-title":"The influence of a mineral oil cationic nanoemulsion or perfluorohexyloctane on the tear film lipid layer and higher order aberrations","author":"Habbe","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.jtos.2023.10.001_bib20","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ophtha.2022.12.021","article-title":"NOV03 for dry eye disease associated with meibomian gland dysfunction: results of the randomized phase 3 GOBI study","volume":"130","author":"Tauber","year":"2023","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2023.10.001_bib21","volume":"89","author":"Page","year":"2021","journal-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews"},{"key":"10.1016\/j.jtos.2023.10.001_bib22","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jtos.2023.10.001_bib23","series-title":"DistillerSR","year":"2022"},{"key":"10.1016\/j.jtos.2023.10.001_bib24","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ophtha.2016.09.025","article-title":"Lifitegrast for the treatment of dry eye disease: results of a phase III, randomized, double-masked, placebo-controlled trial (OPUS-3)","volume":"124","author":"Holland","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2023.10.001_bib25","doi-asserted-by":"crossref","first-page":"8630","DOI":"10.1167\/iovs.11-8027","article-title":"Rasch analysis of the ocular surface disease index (OSDI)","volume":"52","author":"Dougherty","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2023.10.001_bib26","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2147\/OPTH.S398843","article-title":"Validation of a modified national eye Institute grading scale for corneal fluorescein staining","volume":"17","author":"Sall","year":"2023","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jtos.2023.10.001_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10010065","article-title":"Proposed algorithm for management of meibomian gland dysfunction based on noninvasive meibography","volume":"10","author":"Arita","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.jtos.2023.10.001_bib28","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.jtos.2023.10.001_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"The BMJ"},{"key":"10.1016\/j.jtos.2023.10.001_bib30","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.jtos.2023.10.001_bib31","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jtos.2013.07.003","article-title":"Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting","volume":"11","author":"Baudouin","year":"2013","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2023.10.001_bib32","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.ophtha.2017.07.010","article-title":"The pathophysiology of dry eye disease: what we know and future directions for research","volume":"124","author":"Pflugfelder","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2023.10.001_bib33","first-page":"8642","article-title":"Dry eye disease treatment: the role of tear substitutes, their future, and an updated classification","volume":"24","author":"Barabino","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.jtos.2023.10.001_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23052434","article-title":"Artificial tears: biological role of their ingredients in the management of dry eye disease","volume":"23","author":"Labetoulle","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jtos.2023.10.001_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.curtheres.2023.100705","article-title":"Oxygen-carrying capacity of perfluorohexyloctane, a novel eye drop for dry eye disease","volume":"98","author":"Stolowich","year":"2023","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.jtos.2023.10.001_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.curtheres.2023.100704","article-title":"In vitro inhibition of evaporation with perfluorohexyloctane, an eye drop for dry eye disease","volume":"98","author":"Vittitow","year":"2023","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.jtos.2023.10.001_bib37","first-page":"1525","article-title":"Spectroscopic study of perfluorohexyloctane - human meibum interactions","volume":"63","author":"Borchman","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2023.10.001_bib38","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1089\/jop.2021.0102","article-title":"A water-free omega-3 fatty acid eye drop formulation for the treatment of evaporative dry eye disease: a prospective, multicenter noninterventional study","volume":"38","author":"Jacobi","year":"2022","journal-title":"J Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.jtos.2023.10.001_bib39","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.oftal.2020.05.016","article-title":"Effects and safety of perfluorohexyloctane on the eye surface and corneal endothelium","volume":"95","author":"Mateo Orobia","year":"2020","journal-title":"Arch Soc Esp Oftalmol"},{"key":"10.1016\/j.jtos.2023.10.001_bib40","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000499158","article-title":"Semifluorinated alkane eye drops in chronic ocular graft-versus-host disease: a prospective, multicenter, noninterventional study","volume":"63","author":"Eberwein","year":"2020","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.jtos.2023.10.001_bib41","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.ophtha.2015.02.037","article-title":"Comparison of two questionnaires for dry eye symptom assessment: the ocular surface disease index and the symptom assessment in dry eye","volume":"122","author":"Amparo","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2023.10.001_bib42","article-title":"Correlation and level of agreement between the ocular surface disease index and the symptom assessment in dry eye questionnaires: a survey-based study","author":"Rodriguez-Garcia","year":"2023","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.jtos.2023.10.001_bib43","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/aos.14937","article-title":"The prevalence of dry eye in a very old population","volume":"100","author":"Bikbov","year":"2022","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jtos.2023.10.001_bib44","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/archopht.118.5.615","article-title":"Reliability and validity of the ocular surface disease index","volume":"118","author":"Schiffman","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jtos.2023.10.001_bib45","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-033940","article-title":"Reliability and validity of the Japanese version of the Ocular Surface Disease Index for dry eye disease","volume":"9","author":"Midorikawa-Inomata","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.jtos.2023.10.001_bib46","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4067\/s0034-98872020000200187","article-title":"Validation of the ocular surface disease index questionnaire for Chilean patients","volume":"148","author":"Traipe","year":"2020","journal-title":"Rev Med Chile"},{"key":"10.1016\/j.jtos.2023.10.001_bib47","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.18240\/ijo.2021.10.18","article-title":"Validation of the Arabic version of the ocular surface disease index questionnaire","volume":"14","author":"Bakkar","year":"2021","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.jtos.2023.10.001_bib48","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1016\/S0142-9612(01)00167-3","article-title":"The clinical use of viscoelastic artificial tears and sodium chloride in dry-eye syndrome","volume":"22","author":"Nepp","year":"2001","journal-title":"Biomaterials"},{"key":"10.1016\/j.jtos.2023.10.001_bib49","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijpharm.2018.01.019","article-title":"Semifluorinated alkane based systems for enhanced corneal penetration of poorly soluble drugs","volume":"538","author":"Agarwal","year":"2018","journal-title":"Int J Pharm"},{"key":"10.1016\/j.jtos.2023.10.001_bib50","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/j.xphs.2020.03.026","article-title":"Interactions of perfluorohexyloctane with polyethylene and polypropylene pharmaceutical packaging materials","volume":"109","author":"Falk","year":"2020","journal-title":"J Pharmaceut Sci"},{"key":"10.1016\/j.jtos.2023.10.001_bib51","article-title":"Ocular and systemic distribution of 14C- perfluorohexyloctane following topical ocular administration to rabbits","volume":"59","author":"Kroesser","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2023.10.001_bib52","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s40123-023-00669-1","article-title":"Dry eye disease associated with meibomian gland dysfunction: focus on tear film characteristics and the therapeutic landscape","volume":"12","author":"Sheppard","year":"2023","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.jtos.2023.10.001_bib53","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jtos.2017.05.004","article-title":"TFOS DEWS II iatrogenic report","volume":"15","author":"Gomes","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2023.10.001_bib54","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41433-021-01668-x","article-title":"Ocular benzalkonium chloride exposure: problems and solutions","volume":"36","author":"Goldstein","year":"2022","journal-title":"Eye"},{"key":"10.1016\/j.jtos.2023.10.001_bib55","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/ICO.0000000000000695","article-title":"Comparison of the efficacy of fluorometholone with and without benzalkonium chloride in ocular surface disease","volume":"35","author":"Kim","year":"2016","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2023.10.001_bib56","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/ICO.0b013e31815cf651","article-title":"Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears","volume":"27","author":"Kahook","year":"2008","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2023.10.001_bib57","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s12325-008-0078-y","article-title":"Quantitative analysis of conjunctival goblet cells after chronic application of topical drops","volume":"25","author":"Kahook","year":"2008","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtos.2023.10.001_bib58","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000335984","article-title":"Reduced in vivo ocular surface toxicity with polyquad-preserved travoprost versus benzalkonium-preserved travoprost or latanoprost ophthalmic solutions","volume":"48","author":"Liang","year":"2012","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.jtos.2023.10.001_bib59","first-page":"291","article-title":"Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients","volume":"3","author":"Horsley","year":"2009","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jtos.2023.10.001_bib60","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/112067210701700311","article-title":"Ocular symptoms and signs with preserved and preservative-free glaucoma medications","volume":"17","author":"Jaenen","year":"2007","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jtos.2023.10.001_bib62","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jtos.2017.08.003","article-title":"TFOS DEWS II report executive summary","volume":"15","author":"Craig","year":"2017","journal-title":"Ocul Surf"}],"container-title":["The Ocular Surface"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012423001325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012423001325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:46:52Z","timestamp":1761540412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542012423001325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":61,"alternative-id":["S1542012423001325"],"URL":"https:\/\/doi.org\/10.1016\/j.jtos.2023.10.001","relation":{},"ISSN":["1542-0124"],"issn-type":[{"value":"1542-0124","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perfluorohexyloctane in dry eye disease: A systematic review of its efficacy and safety as a novel therapeutic agent","name":"articletitle","label":"Article Title"},{"value":"The Ocular Surface","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtos.2023.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}